AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05133817
Drug: Norepinephrine (0.025 μg/kg/min)
RxNorm normalized name: mepivacaine 0.025 MG/ML / norepinephrine 30 MG/ML Injectable Solution
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Trial: NCT05133817
Drug: Norepinephrine (0.05 μg/kg/min)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Trial: NCT05133817
Drug: Norepinephrine (0.075 μg/kg/min)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Trial: NCT05133817
Drug: Norepinephrine (0.1 μg/kg/min)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Trial: NCT04990557
Drug: PD-1 and ACE2 Knockout T Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
Trial: NCT05098886
Drug: DA-5210 10/1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05098886
Drug: DA-5210-R 10/1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05998421
Drug: routine aspirin and heparin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
Trial: NCT06064331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus of 10 ml normal saline over 3 min followed by infusion of equal volume of normal saline in 20 ml syringe
Trial: NCT05369884
Drug: WPQW granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPQW granule, 2 sachets / time, 3 times / day.
Trial: NCT05369884
Drug: WPQW granule simulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPQW granule simulant, 2 sachets / time, 3 times / day.
Trial: NCT05948683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose
Trial: NCT04966546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple syrup with peppermint oil added to match the commercial solution and make it indistinguishable
Trial: NCT05505162
Drug: EE/LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
Trial: NCT06427200
Drug: oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral iron once daily during or after meals as add-on therapy for 12 weeks.
Trial: NCT06427200
Drug: lactoferrin and oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.
Trial: NCT05001022
Drug: ALG-020572
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of ALG-020572
Trial: NCT05001022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of Placebo
Trial: NCT05316428
Drug: TPN171H tablet plus alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
Trial: NCT05316428
Drug: TPN171H tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg TPN171H tablet QD
Trial: NCT05115123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06650514
Drug: OMO-103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
Trial: NCT05013385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05345964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take Placebo orally(once daily) on Day 1
Trial: NCT05345964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take Placebo orally (once daily) from day 1 to day 7
Trial: NCT04916431
Drug: mRNA-6231
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile frozen liquid dispersion for injection
Trial: NCT04707157
Drug: LY3556050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given orally
Trial: NCT04707157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given orally
Trial: NCT06033742
Drug: HS-10374-matched placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
Trial: NCT05030363
Drug: ALDH enzyme supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALDH enzyme (PICOZYMEQ™)
Trial: NCT06553664
Drug: Treat with Vibrabot capsules for at least 7 weeks
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
Trial: NCT04501770
Drug: Cohort 8 of M802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
Trial: NCT05344170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
Trial: NCT06264882
Drug: Transdermal Estradiol Patch
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to \~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
Trial: NCT06264882
Drug: Transdermal Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
Trial: NCT05648994
Drug: Cyclophosphamide Capsules
RxNorm normalized name: Cyclophosphamide Capsules
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regime
Trial: NCT06402708
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.
Trial: NCT04169360
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White, oblong 300 mg tablet
Trial: NCT05678036
Drug: Opioid maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A reform dramatically expanding access to opioid maintenance treatment (with methadone or buprenorphine) in the region.
Trial: NCT06496815
Drug: PD-1,PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 will be used as previous (if have).
Trial: NCT05061836
Drug: 1.25%Dextrose equivalence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
Trial: NCT05061836
Drug: 2.5%Dextrose equivalence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
Trial: NCT05061836
Drug: Dextrose 5
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5%dextrose in normal saline (5%DNSS) infused with maintenance rate
Trial: NCT05100628
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
Trial: NCT05447494
Drug: High-dose CAN103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations.
Trial: NCT05886660
Drug: Placebo Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will self-administer Placebo Nasal Gel.
Trial: NCT05886660
Drug: Placebo Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
Trial: NCT05660720
Drug: Placebo (orelabrutinib tablet simulator)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as 8 tablets (400mg).
Trial: NCT06118684
Drug: EP395 (Part A and B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP395 (test product) oral capsule 125 mg. Part A: Dose: 1 capsule as a single dose on Day 1 and Day 14, total daily dose: 125 mg.~Part B: Dose: 3 capsules once daily on Days 9 to 28, total daily dose: 375 mg.
Trial: NCT04788654
Drug: Celebrex, acetaminophen, and dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.
Trial: NCT05917561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a month, infusion for 36 weeks
Trial: NCT06486623
Drug: Black chokeberry extract in capsules with 18% standardization of the anthocyanins content
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan.
Trial: NCT05831449
Drug: Naropin, 0.5% Injectable Solution
RxNorm normalized name: Naropin, 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
Trial: NCT05831449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
Trial: NCT05115838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo implantable rod placed subdermally on the upper arm.
Trial: NCT05308979
Drug: OnabotulinumtoxinA 100 UNT [Botox]
RxNorm normalized name: onabotulinumtoxinA 100 UNT [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
Trial: NCT05093933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
Trial: NCT05937178
Drug: ETV/TAF/TDF/TMF/IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
Trial: NCT06290375
Drug: HSK21542 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-daily
Trial: NCT06290375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-daily
Trial: NCT06561009
Drug: Anti-BAFFR CART
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-BAFFR CART
Trial: NCT04643067
Drug: KPG-818 mid dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
Trial: NCT04643067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the comparative arm.
Trial: NCT05084911
Drug: Pyramax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyronaridine-Artesunate(180/60mg) tablet for 3days.
Trial: NCT05084911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet for 3days.
Trial: NCT06331299
Drug: UGN-103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-103 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Trial: NCT04350177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration gelatin capsule
Trial: NCT05234606
Drug: SBT6290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles
Trial: NCT06219577
Drug: Systane Complete Multi-Dose PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyedrop
Trial: NCT06219577
Drug: Walgreen's Lubricant Balance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyedrop
Trial: NCT04430569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
Trial: NCT06228963
Drug: Triple therapy for eradication of Helicobacter Pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)
Trial: NCT06176534
Drug: Experimental: chemotheyapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
Trial: NCT06176534
Drug: Active Comparator: endocrine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
Trial: NCT04800562
Drug: PCS499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCS499 900mg twice a day with food
Trial: NCT04860635
Drug: F14 (sustained release celecoxib)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib in BEPO® drug delivery system
Trial: NCT05633745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Doses
Trial: NCT05268289
Drug: Placebo + standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken for 52 Weeks
Trial: NCT06372457
Drug: Approved Hypertrophic Cardiomyopathy drug treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per product label
Trial: NCT05171257
Drug: IV antibiotic treatment from prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receiving same IV antibiotic treatment from prior
Trial: NCT05171257
Drug: differing IV antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receiving differing IV antibiotics from prior
Trial: NCT04268121
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
Trial: NCT05728541
Drug: SYH2043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
Trial: NCT06241833
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of PPI concomitant with DAPT
Trial: NCT04808531
Drug: NanaBis™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
Trial: NCT04808531
Drug: Placebo Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Trial: NCT04808531
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Trial: NCT05433506
Drug: HU6 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six subjects will receive a tablet formulation.
Trial: NCT05433506
Drug: HU6 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six subjects will receive the capsule formulation
Trial: NCT05654922
Drug: ARINA-1
RxNorm normalized name: ZOSTERA MARINA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
Trial: NCT05755282
Drug: Post-market foam alcohol-based hand sanitizer #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
Trial: NCT06284122
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 Day 1 from C1 to C6
Trial: NCT06284122
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 Day 1 from C1 to C6
Trial: NCT04817111
Drug: MIB-626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) 500 mg Tablets, By Mouth, Daily
Trial: NCT05954442
Drug: Investigator's Choice of Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.
Trial: NCT04994951
Drug: Triamcinolone Acetonide Acetate and Urea Cream.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g/tube and CalcipotriolOintment,10g/tube are used alternately.
Trial: NCT04994951
Drug: Qing-Re-Liang-Xue Decoction.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
Trial: NCT00000885
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05244798
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
Trial: NCT05106309
Drug: 10 mg CVL-231 as IR formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT05106309
Drug: 30 mg CVL-231 Target Release, Fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT01411254
Drug: Betamethasone Microsphere (DE-102） Low Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01411254
Drug: Betamethasone Microsphere (DE-102） High Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05007132
Drug: Trifluridine/Tipiracil Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
Trial: NCT01411254
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05279742
Drug: MANP
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [MANPOWER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection 5 µg/Kg
Trial: NCT05279742
Drug: Injection Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection that contains no active ingredient
Trial: NCT05251090
Drug: FRSW107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU/kg, a single dose.